new psychoactive substances

Size: px
Start display at page:

Download "new psychoactive substances"

Transcription

1 image courtesy of TicTac.org new psychoactive substances

2 new psychoactive substances New psychoactive substances (NPS) (designer drugs, research chemicals, legal highs ) have been emerging onto the recreational drug scene at an unprecedented rate. In parallel the number of substances notified to the Early Warning System (EWS) for the first time is increasing year on year; 13 in 2008, 24 in 2009, 41 in 2010, 49 in 2011 and 73 in It is predicted that this number will exceed 80 for Law enforcement, policy makers, scientists, clinicians, drug support workers and others actively working in this field are left floundering under the ingenuity of the market, and the speed at which it reacts. In general legislation has been effective in reducing use and availability of the controlled substance, but inadvertently spores a plethora of new compounds the substitution effect. As producers of designer drugs have become more creative, so have our methods for monitoring the emergence and usage of these substances. Since user reports are inherently unreliable and ingredients of legal highs are highly variable, analytically confirmed reports are critical for accurate information gathering. However, the availability of reference materials is frequently cited as a major challenge for those tasked with detection. Chiron strive to meet customer demand for NPS reference materials, and work closely with clinical and forensic institutions to this effect. This mini-catalogue lists a wide range of standards for NPS and associated substances [1]. [1] King, L.A. & Nutt, D.J. Deaths from legal highs : a problem of definitions, The Lancet, Volume 383, Issue 9921, Page 952, 15 March 2014, doi: /s (14) New psychoactive substance: a new narcotic or psychotropic drug, in pure form or in preparation, that is not controlled by the 1961 United Nations Single Convention on Narcotic Drugs or the 1971 United Nations Convention on Psychotropic Substances, but which may pose a public health threat comparable to that posed by substances listed in these conventions (Council Decision 2005/387/JHA). EMCDDA Definition

3 Amphetamines ME 100µg/mL K-ME 1000µg/mL DL-Amphetamine, Free base (+/-)-Amphetamine MG MG 50mg MG 100mg ME K-ME DL-Amphetamine Hydrochloride (+/-)-Amphetamine HCl MG MG 50mg MG 100mg MG DL-Amphetamine-d3 Hydrochloride (+/-)-Amphetamine-d3 HCl MG 50mg MG 100mg ME K-ME DL-Amphetamine-d5 Hydrochloride (+/-)-Amphetamine-d5 HCl MG MG 50mg MG 100mg (R)-(-)-Amphetamine Hydrochloride (S)-(+)-Amphetamine Hydrochloride DL-Amphetamine{ring13C6} Sulphate (+/-)-DL-Amphetamine{ring13C6} Sulphate ME ME ME 50µg Base/mL K-ME K-ME MG 5mg ME 100µg/mL DL-Acetylamphetamine (+/-)-Acetylamphetamine K-ME 1000µg/mL MG ME K-ME DL-Amphetamine Sulfate (+/-)-Amphetamine Sulfate MG MG 50mg MG 100mg ME DL-2-Bromoamphetamine Hydrochloride (+/-)-2-Bromoamphetamine HCl K-ME MG ME DL-3-Bromoamphetamine Hydrochloride (+/-)-3-Bromoamphetamine HCl K-ME MG ME DL-4-Bromoamphetamine Hydrochloride (+/-)-4-Bromoamphetamine HCl K-ME MG MG 50mg DL-4-Fluoroamphetamine DL-2-Fluoroamphetamine Hydrochloride DL-3-Fluoroamphetamine Hydrochloride (+/-)-4-Fluoroamphetamine (+/-)-2-Fluoroamphetamine HCl (+/-)-3-Fluoroamphetamine HCl ME ME ME 100µg/mL MG MG MG ME DL-2-Methoxyamphetamine Hydrochloride (+/-)-2-Methoxyamphetamine HCl K-ME MG ME DL-3-Methoxyamphetamine Hydrochloride (+/-)-3-Methoxyamphetamine HCl K-ME MG DL-2-Methylamphetamine Hydrochloride DL-3-Methylamphetamine Hydrochloride DL-4-Methylamphetamine Hydrochloride DL-PMA Hydrochloride (+/-)-2-Methylamphetamine HCl (+/-)-3-Methylamphetamine HCl (+/-)-4-MA, PMA, PAL-313, Aptol (+/-)-PMA HCl ME ME ME ME MG MG MG MG (+/-)-{13C6}-PMA Hydrochloride Ring-{13C6}-4-Methoxyamphetamine HCl ME 50µg Base/mL Methyl Amphetamines ME K-ME DL-Methamphetamine Hydrochloride (+/-)-Methamphetamine HCl MG MG 50mg MG 100mg DL-Methamphetamine-d3 Hydrochloride (+/-)-Methamphetamine-d3 HCl ME ME K-ME DL-Methamphetamine-d5 Hydrochloride (+/-)-Methamphetamine-d5 HCl MG MG 50mg MG 100mg DL-Methamphetamine{ring13C6} Hydrochloride (+/-)-Methamphetamine{ring13C6} HCl ME 50µg Base/mL MG 5mg ME (R)-(-)-Methamphetamine Hydrochloride K-ME MG ME (S)-(+)-Methamphetamine Hydrochloride K-ME MG DL-2-Fluoromethamphetamine Hydrochloride (+/-), DL-2-FMA HCl MG DL-3-Fluoromethamphetamine Hydrochloride (+/-), DL-3-FMA HCl MG ME DL-4-Fluoromethamphetamine Hydrochloride (+/-), DL-4-FMA HCl K-ME MG

4 Methyl Amphetamines Continued ME DL-2-Bromomethamphetamine Hydrochloride 1-(2-Bromophenyl)-N-methylpropan-2-amine HCl K-ME MG ME DL-3-Bromomethamphetamine Hydrochloride 1-(3-Bromophenyl)-N-methylpropan-2-amine HCl K-ME MG ME DL-4-Bromomethamphetamine Hydrochloride 1-(4-Bromophenyl)-N-methylpropan-2-amine HCl K-ME MG DL-2-Methoxymethamphetamine Hydrochloride DL-3-Methoxymethamphetamine Hydrochloride DL-4-Methoxymethamphetamine Hydrochloride (+/-), DL-2-MeOMA HCl, (+/-), DL-OMMA HCl (+/-), DL-3-MeOMA HCl, (+/-), DL-MMMA HCl (+/-)-PMMA HCl K-ME K-ME ME 100µg Acid/mL MG MG MG Ring-{13C6}-4-Methoxymethamphetamine Hydrochloride (+/-)-{13C6}-PMMA HCl ME 50µg Acid/mL DL-2-Methylmethamphetamine Hydrochloride DL-3-Methylmethamphetamine Hydrochloride (+/-), DL-2-MMA HCl (+/-), DL-3-MMA HCl K-ME K-ME MG MG DL-4-Methylmethamphetamine Hydrochloride (+/-), DL-4-MMA HCl (Free base) MG 3,4-Methylenedioxymethamphetamine ME (+/-)-MDMA Hydrochloride (+/-)-MDMA Hydrochloride-d5 3,4-Methylenedioxymethamphetamine HCl, Ecstasy HCl 3,4-Methylenedioxymethamphetamine HCl-D5, Ecstasy HCl-d K-ME MG MG 50mg MG 100mg ME K-ME MG MG 50mg MG 100mg D-MDMA Hydrochloride (+), D-3,4-Methylenedioxymethamphetamine, D-Ecstasy ME L-MDMA Hydrochloride (-), L-3,4-Methylenedioxymethamphetamine, L-Ecstasy ME (+/-)-{13C6}-MDMA Hydrochloride Ring-{13C6}-3,4- Methylenedioxymetamphetamine HCl ME 50µg Base/mL ME (+/-)-MDEA Hydrochloride 3,4-Methylenedioxyethylamphetamine HCl K-ME MG (+/-)-{13C6}-MDEA Hydrochloride ring-13c6-3,4-methylenedioxyethylamphetamine HCl ME 50µg Base/mL ME (+/-)-MDA Hydrochloride K-ME MG ME (+/-)-MDA Hydrochloride-d K-ME MG D-MDA Hydrochloride (+)-3,4-Methylenedioxyamphetamine HCl ME L-MDA Hydrochloride (-)-3,4-Methylenedioxyamphetamine HCl ME (+/-)-{13C6}-MDA Hydrochloride Ring-{13C6}-3,4-Methylenedioxyamphetamine HCl ME 50µg Base/mL Ephedrine (1R,2S)-(-)-Ephedrine ME 100µg/mL (1R,2S)-(-)-Ephedrine Hydrochloride G 1G (1R,2S)-(-)-Ephedrine-d6 Hydrochloride (dimethyl-d6) (1S,2R)-(+)-Ephedrine Hydrochloride ME ME MG G 5mg 1G (1S,2R)-(+)-Ephedrine-d3 Hydrochloride(N-methyl-d3) ME (1R,2S)-(-)-Norephedrine L-(-)-Norephedrine, L-(-)-Phenylpropylamine ME 100µg/mL MG DL-Norephedrine Hydrochloride MG 100mg (1R,2S)-(-)-N-Methylephedrine ME 100µg/mL (1S,2S)-(+)-Pseudoephedrine ME 100µg/mL (1S,2S)-(+)-Pseudoephedrine-d3 Hydrochloride (N-methyl-d3) ME (1R,2R)-(-)-Pseudoephedrine ME 100µg/mL (1R,2R)-(-)-Pseudoephedrine-d3 Hydrochloride (N-methyl-d3) ME D-Norpseudoephedrine Hydrochloride Cathine HCl ME MG

5 Cathinones (+/-)-Cathinone Hydrochloride Benzoylethanamine HCl ME MG (+/-)-Cathinone Hydrochloride-d MG BDB Benzodioxolylbutanamine, 1-(1,3-Benzodioxol-5- yl)butan-2-amine, MBDB metabolite MG Butylone Hydrochloride β-keto MBDB HCl MG Ethylone β-keto MDEA ME 100µg/mL MG 5mg 2-Fluoromethcathinone 2-FMC MG 4-Hydroxymethcathinone MG MBDB N-Methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane MG Methcathinone Hydrochloride ME MG 4-Methylethcathinone Hydrochloride 4-MEC HCl (Free base) MG 1mg ME Mephedrone Hydrochloride 4-Methylmethcathinone HCl MDPV Methylenedioxypyrovalerone, 1-(1,3-Benzodioxol- 5-yl)-2-(1-pyrrolidinyl)-1-pentanone HCl (Free base) α-pvp Hydrochloride α-pyrrolidinopentiophenone HCl K-ME MG MG 25mg K-ME MG ME MG 2C Phenethylamines ME 2C-B Hydrochloride 4-Bromo-2,5-dimethoxyphenethylamine HCl MG {13C6}-4-Bromo-2,5-dimethoxyphenethylamine Ring-{13C6}-2C-B Hydrochloride ME 50µg Base/mL HCl ME 2C-H Hydrochloride 2,5-Dimethoxyphenethylamine HCl MG Ring-{13C6}-2C-H Hydrochloride {13C6}-2,5-Dimethoxyphenethylamine HCl ME 50µg Base/mL ME 2C-I Hydrochloride 2,5-Dimethoxy-4-iodophenethylamine HCl MG Ring-{13C6}-2C-I Hydrochloride {13C6}-2,5-Dimethoxy-4-iodophenethylamine HCl ME 50µg Base/mL Bk-2C-B 2-Amino- 1- (4- bromo- 2, 5- dimethoxyphenyl) ethanone ME 100µg/mL K-ME 1000µg/mL MG 25C-NBOH Hydrochloride 2C-C-NBOH HCl MG ME 25C-NBOMe Hydrochloride 2C-C-NBOMe HCl, BOM 2C-C, Climbi K-ME MG MG 100mg 25E-NBOMe Hydrochloride 2C-E-NBOMe HCl, BOM 2C-E MG 100mg 2C-T-2 Hydrochloride 2,5-dimethoxy-4-ethylthiophenethylamine MG 100mg Indanes 2-AI MDAI MDAI Hydrochloride MMAI Hydrochloride 2-Aminoindane 5,6-Methylenedioxy-2-aminoindane 5,6-Methylenedioxy-2-aminoindane HCl 5-Methoxy-6-methyl-2-aminoindane HCl ME K-ME K-ME ME 100µg/mL 1000µg/mL K-ME MG MG K-ME 1000µg/mL Benzofuries (APBs and APDBs) 4-APB and 6-APB (Free base) 4- and 6-APB isomer mix / MG 5-APB Hydrochloride α-methyl-5-benzofuranethanamine HCl APB oxalate α-methyl-5-benzofuranethanamine oxalate, 5-(2-Aminopropyl)benzofuran oxalate (Free amine) 6-APB Hydrochloride α-methyl-6-benzofuranethanamine HCl EAPB 5- Benzofuranethanamine, N- ethyl- α- methyl EAPB 6- Benzofuranethanamine, N- ethyl- α- methyl ME K-ME ME K-ME MG ME K-ME MG ME 100µg/mL K-ME 1000µg/mL MG Please enquire

6 Piperazines Piperazine Benzoylpiperazine Benzoylpiperazine-2,2,3,3,5,5,6,6-d8 BZP BZP-D K-ME K-ME ME 1000µg/mL 1000µg/mL 100µg/mL G MG MG 1g ME 3-Chlorophenylpiperazine Hydrochloride m-cpp HCl K-ME MG ME 1-(2,5-Dimethoxybenzyl)piperazine Hydrochloride K-ME MG ME 1-(4-Fluorophenyl)piperazine dihydrochloride FPP K-ME MG para-fluorophenylpiperazine pfpp, 4-fluorophenylpiperazine, 4-FPP, fluoperazine MG 100mg 1-methyl-4-benzylpiperazine Hydrochloride MBZP HCl, Methylbenzylpiperazine HCl MG 100mg ME 100µg/mL 1-(3-Methylbenzyl)piperazine 3-MBZP K-ME 1000µg/mL MG ME 100µg/mL 1-(3-Methoxyphenyl)piperazine 3-MeOPP K-ME 1000µg/mL MG ME 100µg/mL 1-(4-Methoxyphenyl)piperazine 4-MeOPP K-ME 1000µg/mL MG ME 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride Trade name: Trimetazidine K-ME MG Synthetic Cannabinoids AB-PINACA ME 100µg/mL N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(pentyl K-ME 1000µg/mL 1H-indazole)-3-carboxamide MG AB-PINACA Metabolite (1-Pentyl-1H-indazole-3-carbonyl)-L-valine ME 100µg/mL 5F-AB-PINACA ME 100µg/mL N- (1- amino- 3- methyl- 1- oxobutan- 2- yl)- 1- ( K-ME 1000µg/mL fluoropentyl)- 1H- indazole- 3- carboxamide MG ME 100µg/mL AB-CHIMINACA K-ME 1000µg/mL MG AB-FUBINACA N-(4-Fluorobenzyl) analogue of AB-PINACA ME 100µg/mL AB-FUBINACA Metabolite (1-(4-Fluorobenzyl)-1H-indazole-3-carbonyl)-Lvaline ME 100µg/mL A-796,260 LTI-258, [1- [2- (4- morpholinyl)ethyl]- 1H- indol- 3- yl](2, 2, 3, 3- tetramethylcyclopropyl)- methanone MG ME 100µg/mL AB Adamantyl-[1-pentyl-1H-indol-3-yl]methanone K-ME 1000µg/mL MG ME 100µg/mL AB-005 [1- [(1- methyl- 2- piperidinyl)methyl]- 1H- indol K-ME 1000µg/mL yl](2, 2, 3, 3- tetramethylcyclopropyl)- methanone MG 5F-AKB48, APINACA 5-fluoropentyl analog, 5F ME 100µg/mL AKB-48-5F APINACA K-ME 1000µg/mL MG AM-694 AM-1248 AM-2201 [1- (5- fluoropentyl)- 1H- indol- 3- yl](2- iodophenyl) K-ME 1000µg/mL methanone MG ME 100µg/mL 1-Adamantyl-[1-[(1-methyl-2-piperidinyl)methyl] K-ME 1000µg/mL 1H-indol-3-yl]methanone MG ME 100µg/mL (1-Naphthalenyl)-(1-(5-fluoropentyl)-1H-indol K-ME 1000µg/mL MG AM Hydroxypentyl metabolite AM-2201 metabolite ME 100µg/mL AM Hydroxyindole metabolite AM-2201 main metabolite ME 50µg/mL MAM-2201 AM-2233 AM-2233 Hydrochloride APICA 5F-APICA APINACA (2-Iodophenyl)-[1-[(1-methyl-2-piperidinyl)methyl]- 1H-indol-3-yl]methanone, HCl ME 50µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG HU-308 4'-Methyl-AM-2201, [1- (5- Fluoropentyl)- 1H- indol- 3- yl](4- methyl- 1- naphthalenyl)- methanone (2-Iodophenyl)-[1-[(1-methyl-2-piperidinyl)methyl]- 1H-indol-3-yl]methanone SDB-001, 2NE1, JWH 018 adamantyl carboxamide STS-135, N-adamantyl-1-fluoropentylindole-3- Carboxamide AKB-48, N-Adamantyl-1-pentylindazole-3- carboxamide (C8)-CP 47,497 rel-5-(1,1-dimethyloctyl)-2-[(1r,3s)-3- hydroxycyclohexyl]phenol ME 100µg/mL HU-210 1,1-Dimethylheptyl-11-hydroxy-THC ME 100µg/mL 4- [4- (1, 1- dimethylheptyl)- 2, 6- dimethoxyphenyl]- 6, 6- dimethyl- bicyclo[3.1.1]hept- 2- ene- 2- methanol MG

7 Synthetic Cannabinoids Continued ME 100µg/mL JWH Pentyl-2-methyl-3-(1-naphthoyl)indole K-ME 1000µg/mL MG JWH-007 N-(5-Hydroxypentyl) metabolite JWH-007 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-007 COOH JWH-007 PentylCOOH metabolite AN 50µg/mL Acetonitrile JWH-007 COOH-d4 JWH-007 PentylCOOH metabolite-d AN 50µg/mL Acetonitrile JWH-015 JWH-016 (2-Methyl-1-propyl-1H-idol-3-yl)-1- naphthenylmethanone 1-Butyl-2-methyl-3-(1-naphthoyl)indole K-ME 1000µg/mL MG 1000µg/mL ME 100µg/mL K-ME 1000µg/mL MG JWH-016 N-(4-hydroxybutyl) metabolite JWH-016 N-(4-Hydroxybutyl) metabolite AN 50µg/mL Acetonitrile JWH-016 COOH JWH-016 ButylCOOH metabolite AN 50µg/mL Acetonitrile JWH-016 COOH-d4 JWH-016 ButylCOOH metabolite-d AN 50µg/mL Acetonitrile JWH-018 JWH-018-d11 AM-678, 1-Naphthalenyl-(1-pentyl-1H-indol ME 50µg/mL ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL MG 1-Naphthalenyl-(1-pentyl-1H-indol-3- -d11 JWH-018 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-018 COOH JWH-018 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-018 COOH-d4 JWH-018 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-018 methylderivate (2-methylnaphthalene) (2-Methylnaphthalen-1-yl)-(1-pentyl-1H-indol K-ME 1000µg/mL MG JWH-018 Methylderivate N-(5-Hydroxypentyl) metabolite JWH-018 methylderivate N-(5-hydroxybutyl) metabolite AN 50µg/mL Acetonitrile ME 100µg/mL JWH Heptyl-3-(1-naphthoyl)indole K-ME 1000µg/mL MG ME 100µg/mL JWH Naphthalenyl-(1-pentylpyrrol K-ME 1000µg/mL MG JWH ME 100µg/mL 1- naphthalenyl(1- propyl- 1H- indol- 3- yl) ME 1000µg/mL methanone MG JWH-072-N-carboxy JWH-072 N-Propanoic acid metabolite AN 50µg/mL MG 5mg ME 50µg/mL JWH-073 (1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanone ME 100µg/mL K-ME 1000µg/mL MG JWH-073-d9 (1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanoned MG ME 100µg/mL JWH-073 N-(4-Hydroxybutyl) metabolite JWH-073 N-(4-Hydroxybutyl) metabolite AN 50µg/mL Acetonitrile JWH-073 COOH JWH-073 PentylCOOH metabolite, JWH 073 N-butanoic acid metabolite AN 50µg/mL Acetonitrile JWH-073 COOH-d4 JWH-073 PentylCOOH metabolite-d4, JWH 073 N-butanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-073 methylderivate (2-methylnaphthalene) 1-Butyl-3-(2-methyl-1-naphthoyl)indole K-ME 1000µg/mL MG JWH-073 methylderivate N-(4-Hydroxybutyl) metabolite JWH-073 Methylderivate N-(4-hydroxybutyl) metabolite AN 50µg/mL Acetonitrile JWH ME 100µg/mL K-ME 1000µg/mL MG JWH-081 COOH JWH-081 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-081 COOH-d4 JWH-081 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH Pentyl-2-methyl-3-(4-methoxy-1- naphthoyl)indole ME 100µg/mL K-ME 1000µg/mL MG JWH-098 N-(5-Hydroxypentyl) metabolite JWH-098 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-098 COOH JWH-098 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-098 COOH-d4 JWH-098 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-122 (4-Methoxyl-1-naphthalenyl)-(1-pentyl-1H-indol-3- (4-Methyl-1-naphthalenyl)-(1-pentyl-1H-indol ME 100µg/mL K-ME 1000µg/mL MG JWH-122-d11 (4-Methyl-1-naphthalenyl)-(1-pentyl-1H-indol-3- -d ME 100µg/mL JWH-122 N-(4-Hydroxypentyl)-metabolite AN 100µg/mL Acetonitrile JWH-122 N-(5-Hydroxypentyl)-metabolite AN 50µg/mL Acetonitrile JWH-122 COOH JWH-122 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-122 COOH-d4 JWH-122 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH Hexyl-3-(1-naphthoyl)-5-phenyl-pyrrol MG JWH-200 JWH-203 WIN 55,225; (1-[2-(4-morpholinyl)ethyl]-1H-indol K-ME 1000µg/mL yl]-)-naphthalenylmethanone MG 2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl) K-ME 1000µg/mL ethanone MG JWH-203 N-(5-Hydroxypentyl) metabolite JWH-203 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-203 COOH JWH-203 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-203 COOH-d4 JWH-203 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-210 (4-Ethylnaphthalene-1-yl)(1pentyl-1H-indol K-ME 1000µg/mL JWH-210 COOH JWH-210 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH (2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl) K-ME 1000µg/mL ethanone MG JWH-250 N-(5-Hydroxypentyl) metabolite JWH-250 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-250 COOH JWH-250 pentylcooh metabolite AN 50µg/mL Acetonitrile JWH-250 COOH-d4 JWH-250 metabolite-d AN 50µg/mL Acetonitrile JWH (2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)- ethanone ME 50µg/mL Acetonitrile

8 Synthetic Cannabinoids Continued... JWH Pentyl-3-(1-naphthoyl)-5-(2-fluorophenyl)-pyrrol PB-22 QUPIC F-PB-22 5-fluoro QUPIC RCS ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG RCS-4 N-(5-Hydroxypentyl) metabolite RCS-4 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile RCS-4 COOH RCS-N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile RCS-4 COOH-d4 RCS-N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile RCS-4 ortho (2-Methoxyphenyl)-(1-pentyl-1H-indol K-ME 1000µg/mL MG RCS-4 ortho N-(5-Hydroxypentyl) metabolite RCS-4 ortho N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile RCS-4 ortho COOH RCS-4 ortho N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile RCS-4 ortho COOH-d4 RCS-4 ortho N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile RCS-4 meta (3-Methoxyphenyl)-(1-pentyl-1H-indol K-ME 1000µg/mL MG RCS-4 meta N-(5-hydroxypentyl) metabolite RCS-4 meta N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile RCS-4 meta COOH RCS-4 meta N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile RCS-4 meta COOH-d4 RCS-4 meta N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile RCS-4-4C (1-Butyl-1H-indol-3-yl)(4-methoxyphenyl) K-ME 1000µg/mL methanone MG RCS-8 1-(2-Cyclohexylethyl)-3-(2- methoxyphenylacetyl)indole MG UR-144 UR-144 N-(4-Hydroxypentyl) metabolite URB-597 URB ME 100µg/mL KM-X1 or (1-pentylindol-3-yl)-(2,2,3, K-ME 1000µg/mL tetramethylcycloprop MG ME 100µg/mL (1- (4- hydroxypentyl)- 1H- indol- 3- yl)(2, 2, 3, K-ME 1000µg/mL tetramethylcycloprop MG ME 100µg/mL KSD-4103, [3-(3-Carbamoylphenyl)phenyl] N K-ME 1000µg/mL cyclohexylcarbamate MG ME 100µg/mL 6- methyl- 2- [(4- methylphenyl)amino]- 1- benzoxazin K-ME 1000µg/mL 4- one MG WIN Pravadoline K-ME 1000µg/mL WIN mesylate XLR-11 4-hydroxy SR-19, BTM-4, (4-Methoxyphenyl)-(1-pentyl-1Hindol-3- (R)-(5-methyl-3-(morpholinomethyl)-2,3-dihydro- [1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1- methanesulfonate (1- (5- fluoro- 4- hydroxypentyl)- 1H- indol- 3- yl)(2, 2, 3, 3- tetramethylcycloprop XLR-11 5-fluoro UR ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL Benzodiazepines Bentazepam Diclazepam 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-1-methyl- 2H-1,4-benzodiazepin-2-one Etizolam Flubromazepam Nifoxipam 3-hydroxyflunitrazepam Nimetazepam Trade name Erimin Phenazepam Hydroxyphenazepam Phenazepam metabolite Phenazepam 4-oxide Phenazepam metabolite Pyrazolam ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG MG 100mg ME 100µg/mL K-ME 1000µg/mL MG Please enquire ME 100µg/mL K-ME 1000µg/mL MG T 100µg/mL Toluene K-T 1000µg/mL Toluene MG MG 50mg MG 100mg T 100µg/mL Toluene K-T 1000µg/mL Toluene MG T 100µg/mL Toluene K-T 1000µg/mL Toluene MG ME 100µg/mL K-ME 1000µg/mL MG

9 Abused or designer pharmaceuticals ME 100µg/mL Desomorphine Krokodil, Dihydrodeoxymorphine MG Dimethylamylamine Hydrochloride DMAA, Methylhexaneamine MG 100mg Etaqualone Hydrochloride Aolon, Athinzone Gabapentin Trade name Neurontin Gabapentin-d (S)-(+)-Pregabalin Trade name Lyrica (S)-(+)-Pregabalin-d4 (aminomethyl d2; hexanoic acid-2,2-d2) ME MG 25mg K-ME 1000µg/mL mg 25mg mg 100mg G 1g K-ME 1000µg/mL MG 5mg MG ME 100µg/mL K-ME 1000µg/mL MG MG 50mg MG 100mg ME 100µg/mL K-ME 1000µg/mL MG MG 25mg K-ME MG ME MG ME 100µg/mL MG MG 200mg ME MG MG 200mg ME 100µg/mL MG ME MG 5mg ME 100µg/mL K-ME 1000µg/mL MG MG 100mg 3,4-CTMP 3,4-Dichloromethylphenidate MG 3,4-CTMP Hydrochloride 3,4-Dichloromethylphenidate HCl MG Propylhexedrine Hydrochloride Hexahydromethamphetamine, Benzedrex, Obesin MG Norpropylhexedrine Hydrochloride Hexahydroamphetamine MG ME O-Desmethyl cis-tramadol Hydrochloride Tramadol metabolite M K-ME MG 25mg O-Desmethyl tramadol-d6 (racemic) Tramadol metabolite M1-d ME 100µg/mL Hydroxybutyrates Sodium gammahydroxybutyrate GHB Na K-ME 1000µg/mL MG 100mg K-ME 1000µg/mL Sodium gammahydroxybutyrate-d6 GHB-d6 Na MG MG 100mg Sodium gammahydroxybutyrate-1,4-13c2 GHB-13C2 Na K-ME 1000µg/mL MG K-ME 1000µg/mL Butyrolactone GBL, gammabutyrolactone MG MG 100mg K-ME 1000µg/mL Butyrolactone-d6 GBL-d6, gammabutyrolactone-d MG MG 100mg Aryl Cyclohexylamines ME K-ME (+/-)-Ketamine Hydrochloride Trade names Ketanest, Ketaset, and Ketalar MG MG 50mg MG 100mg (S)-(+)-Ketamine Hydrochloride ME (+/-)-Norketamine Hydrochloride Ketamine metabolite ME Methoxetamine (MXE) Cyclohexanone, 2- (ethylamino) - 2- ( K-ME 1000µg/mL methanol methoxyphenyl) MG neat neat Phencyclidine Hydrochloride PCP, "Angel dust" MG Phencyclidine-d5 Hydrochloride ME MG Tryptamines & Related Compounds Methylphenidate Hydrochloride (threo) Ritalin Methylphenidate-d9 Hydrochloride (piperidine-d9), (erythro+threo) Ritalinic acid Hydrochloride (threo) Ritalin-d Ritalinic acid (threo) (Free base) Ritalinic acid (erythro) Ritalinic acid-d9 Hydrochloride (piperazine-d9) (erythro+threo) Ethylphenidate α- Phenyl-2- piperidineacetic acid ethyl ester AMT α-mt, Indopan, α-methyltryptamine Please enquire N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Nmethylpropan-2-amine MG K-ME 1000µg/mL 5-MeO-MiPT 4-Acetylpsilocin fumarate 4-AcO-DMT, psilacetin MG

10 Plant Chemicals Salvinorin A MG ME 100µg/mL (-)-Scopolamine hydrobromide trihydrate Trade names Levo-duboisine, Hyosine MG 100mg MG (+/-)-Cathinone Hydrochloride Benzoylethanamine ME (+/-)-Cathinone Hydrochloride-d MG MG Cathine Hydrochloride D-Norpseudoephedrine HCl ME Other Materials Prolintane Prolintane Nitracaine (R)-(-)-Bromodragonfly Hydrochloride MT-45 Hydrochloride AH-7921 AH-7921-d6 (dimethyl-d6) 1c6, (+)-1-Cyclohexyl-4-( ME diphenylethylpiperazine) HCl MG 5mg 3, 4- Dichloro- N- [[ ME 100µg/mL (dimethylamino) cyclohexyl] methyl] benzamide K-ME 1000µg/mL 3, 4- Dichloro- N- [[ ME 100µg/mL (dimethylamino) cyclohexyl] methyl] benzamide-d K-ME 1000µg/mL ME 100µg/mL Diphenidine K-ME 1000µg/mL MG 10MG Methoxyphenidine ME 100µg/mL (±)-1-[1-(2-Methoxyphenyl) K-ME 1000µg/mL phenylethyl]piperidine MG 2-Methiopropamine 2- Thiopheneethanamine, N, α- dimethyl ME 100µg/mL MG Methiopropamine Hydrochloride MPA HCl MG MG 10MG 4-Methyl-4-methylaminorex p-methyl-4mar MG 3-Diethylamino-2,2-dimethylpropyl-4- nitrobenzoate, 4-nitro-dimethocaine (αr)-8-bromo-α-methyl-benzo[1,2-b:4,5-b']difuran- 4-ethanamine HCl ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG 10MG ME

11 For ordering and information about prices and delivery in your country please contact your local distributor: NPS _v1, 05-14

THE EXPANDING REACH OF THE DESIGNER DRUG MOVEMENT IN 2011: CHALLENGES FOR FORENSIC TOXICOLOGY & CHEMISTRY

THE EXPANDING REACH OF THE DESIGNER DRUG MOVEMENT IN 2011: CHALLENGES FOR FORENSIC TOXICOLOGY & CHEMISTRY THE EXPANDING REACH OF THE DESIGNER DRUG MOVEMENT IN 2011: CHALLENGES FOR FORENSIC TOXICOLOGY & CHEMISTRY Barry K Logan PhD, DABFT, National Director Forensic Services, NMS Labs Willow Grove PA History

More information

Results from the STRIDA project. Matilda Bäckberg PhD, M.Sc.Pharm The Swedish Poisons Information Centre

Results from the STRIDA project. Matilda Bäckberg PhD, M.Sc.Pharm The Swedish Poisons Information Centre Results from the STRIDA project Matilda Bäckberg PhD, M.Sc.Pharm The Swedish Poisons Information Centre Email: Matilda.Backberg@gic.se No. of calls Statistics from telephone service 1800 Amfetamin Amphetamine

More information

E/CN.7/2015/CRP.10 * * 9 December English only V (E) * The present document is reproduced in the form in which it was received.

E/CN.7/2015/CRP.10 * * 9 December English only V (E) * The present document is reproduced in the form in which it was received. 9 December 2015 English only Commission on Narcotic Drugs Reconvened fifty-eighth session Vienna, 9-11 December 2015 Agenda item 6 Implementation of the international drug control treaties: Changes in

More information

Synthetic Drug Threats in the United States: 2018 Update

Synthetic Drug Threats in the United States: 2018 Update Synthetic Drug Threats in the United States: 2018 Update JILL M. HEAD SPECIAL TESTING AND RESEARCH LABORATORY DRUG ENFORCEMENT ADMINISTRATION Objectives 1. Overview of the DEA Emerging Trends & Reference

More information

List Name Chemical Name/AKA Type of drug Notes Substances emerging pre-2010: highlighted compounds are allegedly currently sold online in UK 6-APB

List Name Chemical Name/AKA Type of drug Notes Substances emerging pre-2010: highlighted compounds are allegedly currently sold online in UK 6-APB List Name Chemical Name/AKA Type of drug Notes Substances emerging pre-2010: highlighted compounds are allegedly currently sold online in UK 6-APB 6-(2-aminopropyl)benzofuran Benzo Fury Structurally similar

More information

National Drug Early Warning System (NDEWS) Texas Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center

National Drug Early Warning System (NDEWS) Texas Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center National Drug Early Warning System (NDEWS) Texas Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center Table 1: Demographic and Socio-Economic Characteristics, 2009-2013, ACS Table

More information

Novel psychoactive substances in postmortem toxicology. Pirkko Kriikku, PhD Forensic Toxicologist

Novel psychoactive substances in postmortem toxicology. Pirkko Kriikku, PhD Forensic Toxicologist Novel psychoactive substances in postmortem toxicology Pirkko Kriikku, PhD Forensic Toxicologist Postmortem toxicology in Finland Population: 5.5 million Deaths: ~51 000 per year Medico-legal cause-of-death

More information

Forensic Toxicology Findings in DRDs. Dr Hazel Torrance Manager of the Forensic Toxicology Service Forensic Medicine and Science

Forensic Toxicology Findings in DRDs. Dr Hazel Torrance Manager of the Forensic Toxicology Service Forensic Medicine and Science Forensic Toxicology Findings in DRDs Dr Hazel Torrance Manager of the Forensic Toxicology Service Forensic Medicine and Science Forensic Toxicology at the University of Glasgow Dept of Forensic Medicine

More information

Reports of advisory bodies

Reports of advisory bodies EXECUTIVE BOARD EB136/48 Rev.1 136th session 22 January 2015 Provisional agenda item 15.1 Reports of advisory bodies Expert committees and study groups 1 Report by the Secretariat EXPERT COMMITTEE ON DRUG

More information

SPICE Prevention Issues Measures in Switzerland in the fight against new drugs such as SPICE and bath salts

SPICE Prevention Issues Measures in Switzerland in the fight against new drugs such as SPICE and bath salts SPICE Prevention Issues 2012 Measures in Switzerland in the fight against new drugs such as SPICE and bath salts Werner Bernhard, Lars Ambach, Wolfgang Weinmann Institute of Forensic Medicine, University

More information

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled This document is scheduled to be published in the Federal Register on 11/03/2017 and available online at https://federalregister.gov/d/2017-24009, and on FDsys.gov Billing Code 4410-09-P DEPARTMENT OF

More information

ZCPT S. Jog Rd. Suite Greenacres, FL Phone: (561)

ZCPT S. Jog Rd. Suite Greenacres, FL Phone: (561) ZCPT 4300 S. Jog Rd. Suite 540171 Greenacres, FL 33454 : (561) 343-0789 : ZCPT@ZCLabServices.com Official Use Only Client ID: Toxicology Proficiency Testing Order Form Institution Name (Please Print) CLIA

More information

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled This document is scheduled to be published in the Federal Register on 10/25/2016 and available online at https://federalregister.gov/d/2016-25696, and on FDsys.gov Billing Code 4410-09-P DEPARTMENT OF

More information

Overview and Limitations About Selected Data Sources Found in NDEWS Sentinel Community Site Profile Appendix Data Tables

Overview and Limitations About Selected Data Sources Found in NDEWS Sentinel Community Site Profile Appendix Data Tables Overview and Limitations About Selected Data Sources Found in NDEWS Sentinel Community Site Profile Appendix Data Tables August 2015 NDEWS Coordinating Center NDEWS is funded under NIDA Cooperative Agreement

More information

SEWPROF Roundtable Spain

SEWPROF Roundtable Spain SEWPROF Roundtable Spain John Ramsey TICTAC Communications Ltd St. George s, University of London London SW17 0RE TICTAC s contribution ER Dr. Bram Miserez Discovery and characterisation of NPS Test purchases

More information

Central Asia Synthetic Drugs Situation Assessment. A Report from the UNODC Global SMART Programme

Central Asia Synthetic Drugs Situation Assessment. A Report from the UNODC Global SMART Programme Central Asia Synthetic Drugs Situation Assessment A Report from the UNODC Global SMART Programme December 2017 CONTENTS PREFACE 3 GENERAL ABBREVIATIONS 4 CHEMICAL ABBREVIATIONS 5 EXPLANATORY NOTES 6 EXECUTIVE

More information

National Drug Early Warning System (NDEWS) Los Angeles County Sentinel Community Site Appendix Data Tables, 2015

National Drug Early Warning System (NDEWS) Los Angeles County Sentinel Community Site Appendix Data Tables, 2015 National Drug Early Warning System (NDEWS) Los Angeles County Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center Table 1: Demographic and Socio-Economic Characteristics, 2009-2013,

More information

Substances under Surveillance

Substances under Surveillance Substances under Surveillance The following substances are under surveillance by the World Health Organization (WHO) as they are considered to have the potential to cause public health harm. For ease of

More information

Synthetic Drugs: Overview and Issues for Congress

Synthetic Drugs: Overview and Issues for Congress Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security August 15, 2014 Congressional Research Service

More information

Drugs and The Internet

Drugs and The Internet Issue 2, March 2014 Funded by the Australian Government under the Substance Misuse Prevention and Service Improvement Grants Fund Product of: The National Illicit Drug Indicators Project Recommended Van

More information

In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances

In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances EMCDDA Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and

More information

9889/15 JV/np/tt 1 DG D 2C

9889/15 JV/np/tt 1 DG D 2C Council of the European Union Brussels, 15 June 2015 (OR. en) 9889/15 CORDROGUE 46 FOPOL 152 SAN 185 NOTE From: To: Europol and EMCDDA Delegations No. prev. doc.: 11072/14 Subject: EMCDDA-Europol 2014

More information

The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF

The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF Barry K Logan, Ph.D., NMS Labs National Director, Forensic Services Goals The

More information

Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances

Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances The Challenge of Synthetic Drugs in East and South-East Asia Global SMART Programme 2017 Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances Acknowledgements The Challenge

More information

NPS New Psychoactive Substances

NPS New Psychoactive Substances NPS New Psychoactive Substances NPS are drugs that are synthetically designed to replicate the effects of illegal substances. People may refer to these drugs as legal highs, but many of the substances

More information

Conventional and emerging drugs of abuse: the current situation

Conventional and emerging drugs of abuse: the current situation Conventional and emerging drugs of abuse: the current situation NEW PSYCHOACTIVE SUBSTANCES -THE HIGHS AND LOWS Maritim Hotel, Munich, 12-13 November 2015 Michael Uhl Director of Chemistry Unit Bavarian

More information

New Psychoactive Substances (NPS)

New Psychoactive Substances (NPS) New Psychoactive Substances (NPS) Reference materials 2018 LGC Quality ISO 9001 ISO/IEC 17025 ISO Guide 34 GMP/GLP ISO 13485 ISO/IEC 17043 Science for a safer world LGC is a global leader in measurement

More information

Health Chapter ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH ADMINISTRATIVE CODE CHAPTER CONTROLLED SUBSTANCES

Health Chapter ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH ADMINISTRATIVE CODE CHAPTER CONTROLLED SUBSTANCES Health Chapter 420-7-2 ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH ADMINISTRATIVE CODE CHAPTER 420-7-2 CONTROLLED SUBSTANCES TABLE OF CONTENTS 420-7-2-.01 Authority 420-7-2-.02 Definitions

More information

Changing patterns of new and emerging psychoactive substances in Australia

Changing patterns of new and emerging psychoactive substances in Australia Changing patterns of new and emerging psychoactive substances in Australia Prepared by Rachel Sutherland, on behalf of the Drug Trends team The Drug Trends program is supported by funding from the Australian

More information

Drug Threats in the United States: 2019 Update

Drug Threats in the United States: 2019 Update Drug Threats in the United States: 209 Update J I L L M. H E A D S P E C I A L T E S T I N G A N D R E S E A R C H L A B O R AT O R Y D R U G E N F O R C E M E N T A D M I N I S T R AT I O N Objectives.

More information

Designer Drugs / Research Chemicals / Legal Highs - A survey of recent seizures and an attempt to a more effective handling from a Swiss perspective

Designer Drugs / Research Chemicals / Legal Highs - A survey of recent seizures and an attempt to a more effective handling from a Swiss perspective Toxichem Krimtech 2011;78(Special Issue):167 Designer Drugs / esearch Chemicals / Legal ighs - A survey of recent seizures and an attempt to a more effective handling from a Swiss perspective Michael Bovens,

More information

The Challenge of New Psychoactive Substances (NPS) A Presentation for CAD by Dr Des Corrigan October 2015

The Challenge of New Psychoactive Substances (NPS) A Presentation for CAD by Dr Des Corrigan October 2015 The Challenge of New Psychoactive Substances (NPS) A Presentation for CAD by Dr Des Corrigan October 2015 New Psychoactive Substances Any substance, natural or synthetic which can produce stimulation or

More information

This form should be completed and sent to:

This form should be completed and sent to: International Narcotics Control Board FORM B/P ASSESSMENT OF ANNUAL MEDICAL AND SCIENTIFIC REQUIREMENTS FOR SUBSTANCES IN SCHEDULES II, III AND IV OF THE CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971 (to

More information

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D Secretariat for Multidimensional Security FIFTY-FIFTH REGULAR SESSION April 29 - May 1, 2014 Washington, D.C. OEA/Ser.L/XIV.2.55 CICAD/doc.2106/14

More information

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables The SCS Data Tables are prepared by NDEWS Coordinating Center staff and include information

More information

Synthetic Drug Abuse Prevention Act of A look at how this new legislation is written and how it will affect the narcotics investigator.

Synthetic Drug Abuse Prevention Act of A look at how this new legislation is written and how it will affect the narcotics investigator. What s Inside Volume 3 (August, 2012) Synthetic Drug Abuse Prevention Act of 2012 A look at how this new legislation is written and how it will affect the narcotics investigator. Cathinone Chemical Classes

More information

Synthetic Drugs: Overview and Issues for Congress

Synthetic Drugs: Overview and Issues for Congress Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700

More information

Ecstasy and Related Drugs Reporting System: 2016 Findings

Ecstasy and Related Drugs Reporting System: 2016 Findings Ecstasy and Related Drugs Reporting System: 16 Findings EMCDDA Lisbon Sept 19 th - th Courtney Breen and Amanda Roxburgh on behalf of the Drug Trends Team Drug Trends aims: Document the price, purity,

More information

5923/07 ZH/mp 1 DG H II A

5923/07 ZH/mp 1 DG H II A COUNCIL OF THE EUROPEAN UNION Brussels, 7 February 2007 5923/07 CORDROGUE 13 COVER NOTE from : Europol and EMCDDA to : Horizontal Working Party on Drugs Subject : EMCDDA-Europol 2006 Annual Report on the

More information

New psychoactive substances in Belgium: current status

New psychoactive substances in Belgium: current status New psychoactive substances in Belgium: current status P. Blanckaert Coordinator Belgian Early Warning System on Drugs Rue Juliette Wytsmanstraat 14 1050 Brussels Belgium T +32 2 642 54 08 F +32 2 642

More information

SmartNotes. Why test for synthetic cannabinoids? Synthetic Cannabinoids Facts

SmartNotes. Why test for synthetic cannabinoids? Synthetic Cannabinoids Facts DIAGNOSTICS Synthetic Cannabinoids SmartNotes Why test for synthetic cannabinoids? Synthetic Cannabinoids Facts Largest group of New Psychoactive Substances (NPS) on the market Mind-altering chemicals

More information

National Drug Early Warning System (NDEWS,

National Drug Early Warning System (NDEWS, April 18, 217 CENTER FOR SUBSTANCE ABUSE RESEARCH United States Sentencing Commission Synthetic Cannabinoids, Cathinones, and MDMA Written Testimony: Eric D. Wish, PhD, CESAR Director* CESAR 4321 Hartwick

More information

Hydroxyitraconazole, 100 μg/ml H-110 Hydroxyitraconazole-D 4. , 100 μg/ml H MeO-DiPT, 1.0 mg/ml M-167 Metronidazole-D 3

Hydroxyitraconazole, 100 μg/ml H-110 Hydroxyitraconazole-D 4. , 100 μg/ml H MeO-DiPT, 1.0 mg/ml M-167 Metronidazole-D 3 Cerilliant s new product development process goes beyond just putting a product on the shelf. From synthesis design to performing accelerated and real-time stability studies, our products are designed

More information

SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER, 2014, SPECIAL SESSIONS, AND PROPOSED REGULATIONS

SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER, 2014, SPECIAL SESSIONS, AND PROPOSED REGULATIONS SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER,, SPECIAL SESSIONS, AND PROPOSED REGULATIONS Research current through June 19,. This project was supported by Grant No. G1399ONDCP03A, awarded by the

More information

Recent developments in the detection of harms arising from the use of synthetic cathinonesin Europe

Recent developments in the detection of harms arising from the use of synthetic cathinonesin Europe No conflict of interest Recent developments in the detection of harms arising from the use of synthetic cathinonesin Europe Ana Gallegos 24 September 2015 Lisbon Addictions Conference 2015 Paper session

More information

WHO Expert Committee on Drug Dependence. Thirty-seventh report

WHO Expert Committee on Drug Dependence. Thirty-seventh report W H O T e c h n i c a l R e p o r t S e r i e s 998 WHO Expert Committee on Drug Dependence Thirty-seventh report The World Health Organization was established in 1948 as a specialized agency of the United

More information

APPROVED REGULATION OF THE STATE BOARD OF PHARMACY. LCB File No. R Effective October 31, 2017

APPROVED REGULATION OF THE STATE BOARD OF PHARMACY. LCB File No. R Effective October 31, 2017 APPROVED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R011-17 Effective October 31, 2017 EXPLANATION Matter in italics is new; matter in brackets [omitted material] is material to be omitted.

More information

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082 Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending

More information

Synthetic Drugs: Overview and Issues for Congress

Synthetic Drugs: Overview and Issues for Congress Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Acting Section Research Manager and Specialist in Domestic Security September 16,

More information

Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway

Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway Odd Martin Vallersnes 1,2, Per Sverre Persett 3, Elisabeth Leere Øiestad 4,5,

More information

The EU Early Warning System: 20 years of monitoring New Psychoactive Substances in Europe

The EU Early Warning System: 20 years of monitoring New Psychoactive Substances in Europe The EU Early Warning System: 20 years of monitoring New Psychoactive Substances in Europe Rachel Christie, PhD NDEWS webinar: Examining Global Drug Early Warning Systems, Part 4: Monitoring Drug Trends

More information

PROPOSED REGULATION OF THE BOARD OF PHARMACY LCB FILE NO. R048-18I. The following document is the initial draft regulation proposed

PROPOSED REGULATION OF THE BOARD OF PHARMACY LCB FILE NO. R048-18I. The following document is the initial draft regulation proposed PROPOSED REGULATION OF THE BOARD OF PHARMACY LCB FILE NO. R048-18I The following document is the initial draft regulation proposed by the agency submitted on 03/15/2018 1 Proposed Regulation of the Nevada

More information

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics

More information

SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER, 2014, SPECIAL SESSIONS, AND PROPOSED REGULATIONS

SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER, 2014, SPECIAL SESSIONS, AND PROPOSED REGULATIONS SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER,, SPECIAL SESSIONS, AND PROPOSED REGULATIONS Research current through May 13,. This project was supported by Grant No. G1299ONDCP03A, awarded by the

More information

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D 1 INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D Secretariat for Multidimensional Security FIFTY-SECOND REGULAR SESSION November 28-30, 2012 San José, Costa Rica OEA/Ser.L/XIV.2.52 CICAD/doc.1988/12

More information

Annual report 2012: the state of the drugs problem in Europe

Annual report 2012: the state of the drugs problem in Europe Annual report 2012: the state of the drugs problem in Europe Ilze Jekabsone, MD, MPH Reitox and international cooperation unit 14 December 2012 2 Setting the scene After 30+ years with heroin centre stage

More information

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics

More information

Detection of synthetic cannabinoids in hair

Detection of synthetic cannabinoids in hair Detection of synthetic cannabinoids in hair Alberto Salomone Lisbon, 28 th May 2015 Rise of NPS Arise of critical situations Acute intoxication Workplace testing Driving re-licensing Anti-doping analyses

More information

Minneapolis/St. Paul, Minnesota Drug Abuse Trends: January 2014 Update

Minneapolis/St. Paul, Minnesota Drug Abuse Trends: January 2014 Update Minneapolis/St. Paul, Minnesota Drug Abuse Trends: January 2014 Update Carol Falkowski Drug Abuse Dialogues ABSTRACT Heroin and other opiate addiction continued to escalate in the Twin Cities in 2013.

More information

Proposal for a COUNCIL DECISION

Proposal for a COUNCIL DECISION EUROPEAN COMMISSION Brussels, 12.1.2018 COM(2018) 31 final 2018/0011 (NLE) Proposal for a COUNCIL DECISION on the position to be adopted, on behalf of the European Union, in the sixty-first session of

More information

PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB FILE NO. R011-17

PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB FILE NO. R011-17 PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB FILE NO. R011-17 Workshop April 13, 2017 Explanation Language in bold blue italics is new; language in red text [omitted material] is language to

More information

PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY. LCB File No. R015-13

PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY. LCB File No. R015-13 PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R015-13 Proposed Amendments to NAC 453.510 Purpose of Proposed Amendment: Add certain synthetic cannabis or spice drugs to Schedule I. NAC

More information

This form should be completed and sent to:

This form should be completed and sent to: International Narcotics Control Board FORM B/P ASSESSMENT OF ANNUAL MEDICAL AND SCIENTIFIC REQUIREMENTS FOR SUBSTANCES IN SCHEDULES II, III AND IV OF THE CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971 (to

More information

Designer Drugs Is Your Drug Testing Program Keeping Up? 2

Designer Drugs Is Your Drug Testing Program Keeping Up? 2 The challenges detecting the latest advent of designer drugs has become a moving target. With the increasing number of new compounds entering the United States every year, law enforcement and treatment

More information

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics

More information

Proposal for a COUNCIL DECISION

Proposal for a COUNCIL DECISION EUROPEAN COMMISSION Brussels, 1.12.2014 COM(2014) 716 final 2014/0340 (NLE) Proposal for a COUNCIL DECISION on subjecting 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR) and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine

More information

New drugs in Europe, 2012

New drugs in Europe, 2012 ISSN 1977-7841 New drugs in Europe, 2012 EMCDDA Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA 2012 New drugs in Europe, 2012 EMCDDA Europol 2012 Annual Report on the

More information

Proposal for a COUNCIL DECISION

Proposal for a COUNCIL DECISION EUROPEAN COMMISSION Brussels, 31.8.2016 COM(2016) 548 final 2016/0262 (NLE) Proposal for a COUNCIL DECISION on subjecting the new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)-1Hindole-3-carbonyl]amino]-3,3-dimethylbutanoate

More information

Drug Checking: l esperienza ed i dati. Alberto SALOMONE

Drug Checking: l esperienza ed i dati. Alberto SALOMONE Drug Checking: l esperienza ed i dati Alberto SALOMONE NIGHTLIFE NPS REPLACEMENT EXTASY: Synthetic cathinones LSD: NBOMe series HEROIN: fentanyl and analogs DRUG CHECKING STRATEGY SAMPLE unknown substance

More information

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables The SCS Data Tables are prepared by NDEWS Coordinating Center staff and include information

More information

9668/15 JV/PN/np 1 DGD2C

9668/15 JV/PN/np 1 DGD2C Council of the European Union Brussels, 9 June 2015 (OR. en) Interinstitutional File: 2014/0183 (NLE) 9668/15 CORDROGUE 42 NOTE From: To: Presidency Delegations No. Cion doc.: 16240/14 Subject: Draft Council

More information

DEPARTMENT OF HEALTH IN THE MATTER ORDER FOR SUMMARY ACTION THE SALE AND DISTRIBUTION OF SYNTHETIC CANNABINOIDS

DEPARTMENT OF HEALTH IN THE MATTER ORDER FOR SUMMARY ACTION THE SALE AND DISTRIBUTION OF SYNTHETIC CANNABINOIDS V.. - STATE OF NEW YORK : ---------- DEPARTMENT OF HEALTH IN THE MATTER OF THE SALE AND DISTRIBUTION OF SYNTHETIC CANNABINOIDS --------- x ORDER FOR SUMMARY ACTION v WHEREAS, a cannabinoid is a class of

More information

Clinical Toxicology: An Update

Clinical Toxicology: An Update Clinical Toxicology: An Update Dr. Shaun Greene VICTORIAN POISONS INFORMATION CENTRE AND AUSTIN HOSPITAL CLINICAL TOXICOLOGY SERVICE Drug Abuse in Australasia VICTORIAN POISONS INFORMATION CENTRE AND AUSTIN

More information

NOT FOR HUMAN CONSUMPTION

NOT FOR HUMAN CONSUMPTION HARMFUL NOT FOR PRESENTATION TO ANYONE UNDER 18 NOT FOR HUMAN CONSUMPTION Benzodiazepines Diazepam Estazolam Etizolam Flunitrazepam Clorazepate Flutoprazepam Phenazepam Tetrazepam Nimetazepam Nordazepam

More information

Primer on Synthetic Opioids I/S Brian Dempsey

Primer on Synthetic Opioids I/S Brian Dempsey Primer on Synthetic Opioids I/S Brian Dempsey 412-777-6945 brian.w.dempsey@usdoj.gov Sources - ACOME - Overdose Free PA Website - Pennsylvania Opioid Overdose Reduction Technical Assistance Center (TAC)

More information

Synthetic Drugs and Natural Substances

Synthetic Drugs and Natural Substances Synthetic Drugs and Natural Substances Pat Pizzo Director of Toxicology Alere Toxicology Services The world leader in serving science Who am I? Director of Toxicology at Alere In the field for 47 years

More information

SUBSTANCE MISUSE PROGRAMME. Drug deaths in Wales 2017

SUBSTANCE MISUSE PROGRAMME. Drug deaths in Wales 2017 SUBSTANCE MISUSE PROGRAMME Drug deaths in Wales 2017 About Public Health Wales Public Health Wales exists to protect and improve health and wellbeing and reduce health inequalities for people in Wales.

More information

EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA

EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk-assessment and

More information

10/1/2010. Accredited by ASCLD/LAB International Standard (ISO/IEC 17025) ASCLD/LAB Supplemental. Quality Systems Manual SWGDRUG. Section Methods/SOPs

10/1/2010. Accredited by ASCLD/LAB International Standard (ISO/IEC 17025) ASCLD/LAB Supplemental. Quality Systems Manual SWGDRUG. Section Methods/SOPs Drug Chemistry Section Susan Gross Forensic Science Supervisor Minnesota BCA Drug Chemistry Section - Who we are - What we do - Goals of section - Statistics - Trends Who we are MN Bureau of Criminal Apprehension

More information

WEDINOS Headlines 6,452. wedinos.org 5,806 BULLETIN. Samples. received. Samples. received. Samples. analysed. Samples. rejected

WEDINOS Headlines 6,452. wedinos.org 5,806 BULLETIN. Samples. received. Samples. received. Samples. analysed. Samples. rejected BULLETIN Issue 11 - Jan - Mar 2017 WEDINOS Quarterly Newsletter Collecting, Testing, Informing wedinos.org WEDINOS Headlines TOTAL number of samples received by WEDINOS October 2013 to March 2017 The WEDINOS

More information

Drugs of abuse. Africa Health 23

Drugs of abuse. Africa Health 23 Drugs of abuse Simon L Hill Simon HL Thomas Abstract Toxicity related to drug misuse is a common reason for hospital presentation. The recent emergence of substantial numbers of novel psychoactive substances

More information

GLOBAL S MART UPDATE. Understanding the synthetic drug market: the NPS factor VOLUME 19. March

GLOBAL S MART UPDATE. Understanding the synthetic drug market: the NPS factor VOLUME 19. March GLOBAL S MART UPDATE VOLUME 19 March Understanding the synthetic drug market: the NPS factor EN ES Research 2018 GLOBAL SMART UPDATE About the SMART Update Synthetic drugs constitute one of the most significant

More information

BULLETIN WEDINOS

BULLETIN WEDINOS WEDINOS Quarterly Newsletter Issue 4 Oct-Dec 2014 BULLETIN Collecting, Testing, Inorming wedinos.org The WEDINOS project has been designed or the collection and testing o substances and, most importantly,

More information

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics

More information

AN ACT relating to drugs and declaring an emergency. Be it enacted by the General Assembly of the Commonwealth of Kentucky:

AN ACT relating to drugs and declaring an emergency. Be it enacted by the General Assembly of the Commonwealth of Kentucky: AN ACT relating to drugs and declaring an emergency. Be it enacted by the General Assembly of the Commonwealth of Kentucky: Section 1. KRS 218A.010 is amended to read as follows: (1) "Administer" means

More information

A review of the collision induced dissociation fragmentation and the metabolism of synthetic cathinone derivatives

A review of the collision induced dissociation fragmentation and the metabolism of synthetic cathinone derivatives A review of the collision induced dissociation fragmentation and the metabolism of synthetic cathinone derivatives Nichola Cunningham A thesis submitted in fulfilment of the requirements for the degree

More information

Risk Assessment of Psychoactive Substances: Potentialities and Limitations

Risk Assessment of Psychoactive Substances: Potentialities and Limitations Risk Assessment of Psychoactive Substances: Potentialities and Limitations Leslie A. King, MSc, PhD ReDUse Conference, Vienna, 16 November 2012 1 Overview Why and how risk assessments on psychoactive substances

More information

EMCDDA Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA

EMCDDA Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA EMCDDA Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk-assessment and

More information

EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA

EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk-assessment and

More information

Objectives. Why new drugs? New drugs of abuse: synthetic cannabinoids, stimulants, and 10/14/2015. Describe several new drugs of abuse

Objectives. Why new drugs? New drugs of abuse: synthetic cannabinoids, stimulants, and 10/14/2015. Describe several new drugs of abuse New drugs of abuse: synthetic cannabinoids, stimulants, and more Robert G. Hendrickson, MD Professor, Emergency Medicine, OHSU Program Director, Medical Toxicology Fellowship Associate Medical Director,

More information

2014 Key Australian findings: psychostimulant drug market

2014 Key Australian findings: psychostimulant drug market 214 Key Australian findings: psychostimulant drug market Natasha Sindicich & Lucy Burns National Drug Trends Conference Maritime museum, Sydney Monday, 2 th October, 214 Funded by the Australian Government

More information

Lisa Booze, PharmD, CSPI

Lisa Booze, PharmD, CSPI Lisa Booze, PharmD, CSPI Psychoactive drugs created to avoid existing laws Modify existing drugs or new drugs with different chemical structures >200 new drugs and 8 classes of drugs since 2009 80 new

More information

Crime and Justice. New Psychoactive Substances Evidence Review

Crime and Justice. New Psychoactive Substances Evidence Review Crime and Justice New Psychoactive Substances Evidence Review NEW PSYCHOACTIVE SUBSTANCES EVIDENCE REVIEW Fiona Fraser, Safer Communities Analytical Unit, Scottish Government Scottish Government Social

More information

EMCDDA Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA

EMCDDA Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA EMCDDA Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and

More information

about methodology of monitoring and selecting the web shops see methodology on trend.eu/).

about methodology of monitoring and selecting the web shops see methodology on  trend.eu/). Substance briefing: 6-APB This technical folder provides information on 6-APB. The information provided is based on a number of existing data sources and work undertaken as part of the I-TREND project.

More information

Substance briefing: MPPP

Substance briefing: MPPP Substance briefing: MPPP This technical folder provides information on MPPP. The information provided is based on a number of existing data sources and work undertaken as part of the I-TREND project. Research

More information

The European Early-warning system on new drugs. Dr. R. Sedefov & D. Lopez, Ancona, 18 September 2009

The European Early-warning system on new drugs. Dr. R. Sedefov & D. Lopez, Ancona, 18 September 2009 The European Early-warning system on new drugs Dr. R. Sedefov & D. Lopez, Ancona, 18 September 2009 This presentation A brief introduction to the EMCDDA and EWS What have we learned? The concept of new

More information

VILLAGE OF OBLONG, ILLINOIS ORDINANCE NO O-567

VILLAGE OF OBLONG, ILLINOIS ORDINANCE NO O-567 VILLAGE OF OBLONG, ILLINOIS ORDINANCE NO. 2015-O-567 AN ORDINANCE TO AMEND CHAPTER 27, DIVISION IV OFFENSES INVOLVING DRUGS SYNTHETIC ALTERNATIVE DRUGS OF THE REVISED CODE OF ORDINANCES OF THE VILLAGE

More information

Pills, Powders, Potions and Paraphernalia

Pills, Powders, Potions and Paraphernalia Pills, Powders, Potions and Paraphernalia A P R N 2 0 1 6 C N F E R E N C E W E D N E S D A Y, F E B R U A R Y 1 7, 2 0 1 6 C H A R L E S T N, S C D E M I G A R V I N, B S, P H A R M. D., R. P h., F -ABFT

More information